相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
Ozgur Sahin et al.
CELL RESEARCH (2014)
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-kB Activation, and Is Active in Patient-Derived Xenograft Models
Christopher A. Benetatos et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
Jennifer L. Allensworth et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Clemens Krepler et al.
CLINICAL CANCER RESEARCH (2013)
Adverse events associated with mTOR inhibitors
Nicolas Pallet et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
Hajime Asahina et al.
INVESTIGATIONAL NEW DRUGS (2013)
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells
Anna-Maria Jegg et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Qingfei Wang et al.
CANCER RESEARCH (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Len Neckers et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Leiping Wang et al.
BMC CANCER (2011)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Joan T. Garrett et al.
CANCER BIOLOGY & THERAPY (2011)
Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
Jie Qi et al.
CANCER RESEARCH (2011)
Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer
Ken Takezawa et al.
CLINICAL CANCER RESEARCH (2011)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi et al.
CLINICAL CANCER RESEARCH (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Francisco J. Esteva et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Mitochondria and cell death: outer membrane permeabilization and beyond
Stephen W. G. Tait et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
IAPs - More than just inhibitors of apoptosis proteins
Laurence Dubrez-Daloz et al.
CELL CYCLE (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
Chien-Hsing Lu et al.
CLINICAL CANCER RESEARCH (2007)
The inhibitors of apoptosis (IAPs) as cancer targets
Allison M. Hunter et al.
APOPTOSIS (2007)
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9
Georgios V. Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein function by 17-AAG
A Radujkovic et al.
LEUKEMIA (2005)
Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
17-allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells
G Fumo et al.
BLOOD (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
DC Fingar et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
PM Smith-Jones et al.
NATURE BIOTECHNOLOGY (2004)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
PK Majumder et al.
NATURE MEDICINE (2004)
Regulation of survivin function by Hsp90
P Fortugno et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
K Inoki et al.
GENES & DEVELOPMENT (2003)
Regulation of 17-AAG-induced apoptosis:: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases
R Nimmanapalli et al.
BLOOD (2003)
分享论文
